Biotech entity
Of the tracked stories, 2 of 3 also mention AMT-130, the most common co-covered peer. Coverage clusters in gene-therapy, which accounts for 2 of those 3, with the remainder spread across 1 other category. They are less corroborated than the beat average, carrying 2.3 original sources each against 3.6 for the same window.
Last mentioned: Aug 5, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 33 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 2 of 3 also mention AMT-130, the most common co-covered peer. Coverage clusters in gene-therapy, which accounts for 2 of those 3, with the remainder spread across 1 other category. They are less corroborated than the beat average, carrying 2.3 original sources each against 3.6 for the same window. That works out to roughly 0.1 stories per week across a 168-day span. At 6, the average consequence score sits below the same-window beat average of 6.2. This profile follows 3 Biotech stories mentioning uniQure N.V. across the period from February 19, 2026 to August 5, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 677 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering uniQure N.V.. Shared-story counts are live from our verified record — not editorial picks.
Anticipated Amended Complaint
Expected filing of detailed allegations following the appointment of lead plaintiffs.
FDA accepts AMT-130 Phase 1/2 data for BLA
The FDA reversed its earlier requirement for additional data, agreeing existing clinical data supports a near-term BLA submission for Huntington’s gene therapy.
SEC filings and market close
Stock closes at $27.57, up 2.8%; SEC Form 4 filings reveal the three insider transactions.
Insider sales executed
Directors Kaye, Balachandran, and Meek each sell 1,993 shares at $27.06.
Q1 2026 earnings
uniQure reports revenue of $3.56M (miss) and EPS of -$0.85 (beat by $0.03); net margin remains deeply negative.
Lead Plaintiff Deadline
Final date for eligible investors to file applications in the class action lawsuits against QURE and KD.
RBC upgrade
RBC Capital upgrades uniQure from sector perform to outperform, raising price target from $11 to $35.
Legal Alert Issued
ClaimsFiler reminds shareholders of upcoming deadlines for lead plaintiff applications.
Planned BLA submission in Q3 2026
UniQure intends to submit a Biologics License Application for AMT-130 in the third quarter, pending alignment meeting on confirmatory study design.
Three uniQure directors each offloaded 1,993 shares at $27.06, pocketing a combined $162K. The gene therapy company’s stock trades above key moving averages after an RBC upgrade, but sales hint at insider caution amid heavy cash burn.
Source: dailypolitical.com · themarketsdaily.com
FDA’s acceptance of existing clinical data for uniQure’s AMT-130 gene therapy signals a major regulatory win, with the company on track for a BLA submission in Q3 2026 and a potential first-in-class approval for Huntington’s disease.
Investors in uniQure N.V. and Kyndryl Holdings have until April 13, 2026, to file as lead plaintiffs in securities class action lawsuits following significant stock losses. The litigation highlights increasing regulatory and disclosure pressures on biotech firms specializing in complex gene therapies.
uniQure N.V. is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
